rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    ANNX
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Annexon Reports Third Quarter 2026 Financial Results, Business Updates and Key Anticipated Milestones
      Nov 9Yahoo FinanceANNX
      Annexon, Inc. (ANNX) Discusses Vonaprument Phase III ARCHER II Trial in Geographic Atrophy - Slideshow (NASDAQ:ANNX) 2026-11-07

      2026-11-07. The following slide deck was published by Annexon, Inc.

      Nov 7Seeking AlphaANNX
      Annexon Eyes Q4 2026 Phase III Readout for Vision-Preserving GA Drug
      Nov 4Yahoo FinanceANNX
      Annexon schedules investor event on phase 3 trial Nov. 3 By Investing.com
      Oct 28Investing.comANNX
      Annexon to Host Virtual Investor Event on November 3, 2026: Vonaprument for the Treatment of Geographic Atrophy - Highlighting Key Aspects of Phase 3 ARCHER II Trial

      BRISBANE, Calif., Oct. 28, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people worldwide, today announced that it will host a virtual investor event on Tuesday, November 3, 2026 at 11:00 AM ET regarding the ARCHER II Phase 3 program. To register, click here. Company management will highlight the Phase 3 ARCHER II clinical trial

      Oct 28Yahoo FinanceANNX
      H.C. Wainwright raises Annexon stock price target on GBS approval prospects
      Oct 20Investing.comANNX
      JPMorgan raises Annexon Biosciences price target on trial data
      Sep 30Investing.comANNX
      Wall Street Analysts Are Bullish on Top Healthcare Picks

      Detailed price information for Annexon Inc (ANNX-Q) from The Globe and Mail including charting and trades.

      Sep 30The Globe and MailANNXMMSI
      Annexon: Preserving Patient Function Is The Real Investment Opportunity (NASDAQ:ANNX)

      Annexon bets on functional outcomes in geographic atrophy & GBS; ARCHER II vision endpoints read out in Q4 2026. Click for more on ANNX stock.

      Sep 27Seeking AlphaANNX
      Annexon presents vonaprument data at retina meeting
      Sep 24Investing.comANNX
      Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

      BRISBANE, Calif., Sept. 16, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people worldwide, today announced that it has granted inducement to two new non-executive employees under the terms of the 2022 Employment Inducement Award Plan. The equity awards were approved on September 12, 2026, in accordance with Nasdaq Listing Rule

      Sep 16Yahoo FinanceANNX
      Annexon at Cantor Fitzgerald conference: eye data, gbs progress
      Sep 10Investing.comANNX
      Annexon at Wells Fargo 21st annual healthcare conference: late-stage push
      Sep 9Investing.comANNXWFC
      Annexon to Participate in Upcoming September Investor Conferences

      BRISBANE, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people worldwide, today announced that Douglas Love, Esq., president & chief executive officer, will participate in fireside chats during the following September investor conferences: Wells Fargo 21st Annual Healthcare Conference on Wednesday, September 9,

      Sep 2Yahoo FinanceANNX
      What Annexon (ANNX)'s Dual-Endpoint ARCHER II Update Means For Shareholders

      In August 2026, Annexon reported a higher second-quarter net loss of US$55.35 million but a lower year-to-date loss of US$99.49 million, while updating investors on its ongoing Phase 3 ARCHER II trial and new open-label extension study for vonaprument in geographic atrophy. A distinctive aspect of this update is Annexon’s dual primary endpoint design at Months 15 and 24 for ARCHER II, paired with vonaprument’s FDA Fast Track and EMA PRIME designations, which together clarify a globally...

      Aug 24Yahoo FinanceANNX

      This is the newest page. Registered accounts read further back.